IFNA1 and depressive symptom measurement: Whilst clearly efficacious, the systemic delivery of IFNα not only generates an anti-viral response in the liver, but also results in leukocyte activation in the blood leading to adverse responses to the therapy including cytokine release, flu-like symptoms and depression.